Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Melanoma 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Thyroidectomy 4Iodine-131 4trametinib 3dabrafenib 3apatinib 3anlotinib 2Surgical Procedures, Operative 2Blood Specimen Collection 2Biopsy, Large-Core Needle 2toripalimab 1tislelizumab 1surufatinib 1regorafenib 1penpulimab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1famitinib 1camrelizumab 1Ultrasonography 1Thyroxine 1Thyrotropin Alfa 1Sunitinib 1Second Harmonic Generation Microscopy 1Routinely Collected Health Data 1Rosiglitazone 1Robotic Surgical Procedures 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Thyroid Neoplasms × famitinib × Clear all
NCT06146985 2023-11-28

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

Ruijin Hospital

Phase 2 Unknown
67 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡